Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pernix Subsidiaries Receives Approval For VITUZ, Mefenamic Acid Capsules

RELATED NEWS
Trade PTX now with 

Hawthorn Pharmaceuticals, Inc., a subsidiary of Pernix Therapeutics Holdings, Inc. (PTX: Quote) Thursday said it has received approval from the U.S. Food and Drug Administration, or FDA, for VITUZ Oral Solution.

VITUZ solution is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older.

The company also said that its subsidiary, Cypress Pharmaceuticals, Inc., has been granted final approval by the FDA for Mefenamic Acid Capsules USP, 250 mg, a generic version of Ponstel Capsules, 250 mg, indicated for relief of mild-to-moderate pain in patients treated of primary dysmenorrhea.

"VITUZ broadens our cough and cold product line and is our first NDA approved by the FDA, since the acquisition of Hawthorn and Cypress, " said Cooper Collins, President, CEO.

Launch of the new treatment option for cough and cold symptoms is expected prior to the fall of 2012. Mefenamic Acid Capsules are expected to launch in the second quarter.

Click here to receive FREE breaking news email alerts for Pernix Therapeutics Holdings Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A number of major retailers will be open on Thanksgiving for early Black Friday shopping events. Kohl's department stores will kick off Black Friday sales two hours earlier this year, at 6 p.m. Thanksgiving Day, while Macy's, Bon-Ton and Best Buy will open at the same time. J.C. Penney and Sears... Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps, will retain his vice president of product title and work on Twitter's geolocation features, the Wall... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.